# 2025-04031: FDA Issues Lifetime Drug Industry Ban on Convict.

2025-04031, John Warrington Kosolcharoen: Final Debarment Order, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-03-13, effective 2025-03-13; PRIA reads it as touching household money (as of 2026-09-30).

- Canonical: https://policyrisk.com/federal-register/2025-04031
- As of: 2026-09-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-04031
- Title: John Warrington Kosolcharoen: Final Debarment Order
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 11988
- Published: 2025-03-13
- Effective: 2025-03-13
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-30

## In one line

FDA Issues Lifetime Drug Industry Ban on Convict.

## Summary

John Warrington Kosolcharoen is permanently banned by the FDA from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice, so the ban starts on March 13, 2025, and lasts forever unless he applies to end it. This means he can’t be involved in drug approvals or related work, impacting his career and any companies he might have worked with.

## Abstract

The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring John Warrington Kosolcharoen from providing services in any capacity to a person that has an approved or pending drug product application including, but not limited to, a biologics license application (BLA). FDA bases this order on a finding that Mr. Kosolcharoen was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Mr. Kosolcharoen was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of December 26, 2024 (30 days after receipt of the notice), Mr. Kosolcharoen has not responded. Mr. Kosolcharoen's failure to respond and request a hearing constitutes a waiver of Mr. Kosolcharoen's right to a hearing concerning this matter.

## Effects PRIA read

- Permanent debarment from drug-related work: cost, high. John Warrington Kosolcharoen is permanently barred from providing services in any capacity to a person that has an approved or pending drug product application, including biologics license applications (BLA). The debarment is effective March 13, 2025, and is based on his felony conviction on Septem…
- Penalties for hiring or using his services: cost, medium. Any person with an approved or pending drug product application who knowingly employs, retains as a consultant or contractor, or otherwise uses the services of Mr. Kosolcharoen during his debarment will be subject to civil money penalties under section 307(a)(6) of the FD&C Act; Mr. Kosolcharoen hi…
- FDA will not accept his abbreviated drug applications: cost, medium. During his period of debarment, FDA will not accept or review any abbreviated new drug application (ANDA) from Mr. Kosolcharoen, except in connection with an audit under section 306(c)(1)(B) of the FD&C Act.
- Right to apply for special termination at any time: benefit, low. Mr. Kosolcharoen may apply at any time for special termination of debarment under section 306(d)(4) of the FD&C Act. Applications can be submitted electronically to regulations.gov (which will be posted publicly) or as written/paper submissions with a designated confidential copy and a public redac…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-04031 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/13/2025-04031/john-warrington-kosolcharoen-final-debarment-order)
- [2025-04031 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-13/pdf/2025-04031.pdf)

## Related
- [Previous: 2025-04030, Jonathan Corbett Cosie: Final Debarment Order](https://policyrisk.com/federal-register/2025-04030)
- [Next: 2025-04032, Advisory Committee on Cemeteries and Memorials, Amended Notice of Meeting](https://policyrisk.com/federal-register/2025-04032)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-04031 (as of 2026-09-30).
